PRESS RELEASE published on 06/21/2025 at 00:00, 1 year 3 months ago Inka Health Co-Founders Publish New Study Advancing Real-World Applicability of Lung Cancer Clinical Trial Outcomes Onco-Innovations subsidiary Inka Health authors significant study on global transportability of clinical trial outcomes to real-world lung cancer populations, published in medRxiv Clinical Trials Lung Cancer Onco-Innovations Inka Health Real-world Outcomes
BRIEF published on 06/14/2025 at 00:05, 1 year 3 months ago Onco-Innovations Collaborates with University of Alberta on Cancer Research Cancer Research Glioblastoma Onco-Innovations PNKP Inhibitor University Of Alberta
BRIEF published on 06/14/2025 at 00:05, 1 year 3 months ago Onco-Innovations collabore avec l'Université de l'Alberta sur la recherche sur le cancer Glioblastome Recherche Sur Le Cancer Onco-Innovations Inhibiteur De PNKP Université De L'Alberta
PRESS RELEASE published on 06/14/2025 at 00:00, 1 year 3 months ago Onco-Innovations Engages the University of Alberta and Cross Cancer Institute to Expand PNKP Inhibitor Research into Hard-to-Treat Cancers Onco-Innovations partners with University of Alberta and Cross Cancer Institute for preclinical study focusing on hard-to-treat cancers, starting with glioblastoma. Research led by Dr. Michael Weinfeld Preclinical Study Glioblastoma Onco-Innovations University Of Alberta Cross Cancer Institute
BRIEF published on 06/06/2025 at 00:05, 1 year 3 months ago Onco-Innovations Launches AI-Oncology Consortium Personalized Cancer Care Predictive Modeling AI In Oncology Multimodal Data Cross-Sector Collaboration
BRIEF published on 06/06/2025 at 00:05, 1 year 3 months ago Onco-Innovations lance un consortium IA-Oncologie Collaboration Intersectorielle Modélisation Prédictive L'IA En Oncologie Données Multimodales Soins Personnalisés Contre Le Cancer
PRESS RELEASE published on 06/06/2025 at 00:00, 1 year 3 months ago Onco-Innovations' Inka Health to Launch Global AI-Oncology Consortium to Advance Predictive Cancer Research Onco-Innovations Limited's subsidiary, Inka Health Corp., launches PROmAI Consortium for AI in oncology to enhance predictive modeling and collaboration among key stakeholders Predictive Modeling Onco-Innovations Limited Inka Health Corp. AI In Oncology PROmAI Consortium
BRIEF published on 05/27/2025 at 00:07, 1 year 3 months ago Onco-Innovations Advances with Manufacturing for PNKP Inhibitor Cancer Research Preclinical Testing Onco-Innovations PNKP Inhibitor Dalton Pharma
BRIEF published on 05/27/2025 at 00:07, 1 year 3 months ago Onco-Innovations progresse dans la fabrication d'un inhibiteur de la PNKP Recherche Sur Le Cancer Onco-Innovations Dalton Pharma Inhibiteur De PNKP Tests Précliniques
PRESS RELEASE published on 05/27/2025 at 00:02, 1 year 3 months ago Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma Onco-Innovations announces commencement of manufacturing for preclinical testing of nanoparticle-formulated PNKP inhibitor technology in collaboration with Dalton Pharma Services Manufacturing Preclinical Testing Onco-Innovations Dalton Pharma Services Nanoparticle
Published on 09/23/2026 at 15:42, 33 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 1 hour 44 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 1 hour 45 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 14:00, 2 hours 15 minutes ago Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers
Published on 09/23/2026 at 13:30, 2 hours 45 minutes ago Engineering Cost Study Validates Commercial-Scale U.S. HPMSM Capital Cost and Establishes EMM Capital Cost for Electric Metals' North Star Manganese Project
Published on 09/23/2026 at 15:41, 33 minutes ago Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 09/23/2026 at 08:00, 8 hours 15 minutes ago Résultats semestriels 2026 - ANR par action : 101,90 €, en progression de 8,18 % - Capitaux propres consolidés : 774,5 M€
Published on 09/22/2026 at 18:00, 22 hours 15 minutes ago Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 18:00, 22 hours 15 minutes ago Résultats consolidés du premier semestre 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 22 hours 30 minutes ago Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026